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Abstract
Background: The exposure of healthcare workers to anticancer drugs such as cyclophosphamide (CPA) is a serious
health concern. Anticancer drug pollution may spread outside biological safety cabinets even when a closed
system is used. The inhalation of vaporized anticancer drugs is thought to be the primary route of exposure.
Therefore, it is important that healthcare workers wear masks to prevent inhalation of anticancer drugs. However,
the permeability of medical masks to vaporized anticancer drugs has not been examined. Furthermore, the
performance differences between masks including activated carbon with chemical adsorptivity and non-activated
carbon masks are uncertain. We investigated activated carbon mask permeability to vaporized CPA, and assessed
whether inhibition of vaporized CPA permeability was attributable to the masks’ adsorption abilities.
Methods: A CPA solution (4 mg) was vaporized in a chamber and passed through three types of masks: Pleated-type
cotton mask (PCM), pleated-type activated carbon mask (PAM), and stereoscopic-type activated carbon mask (SAM);
the flow rate was 1.0 L/min for 1 h. The air was then recovered in 50 % ethanol. CPA quantities in the solution were
determined by liquid chromatography time-of-flight mass spectrometry. To determine CPA adsorption by the mask,
5 cm2 of each mask was immersed in 10 mL of CPA solution (50–2500 μg/mL) for 1 h. CPA concentrations were
measured by high-performance liquid chromatography with ultraviolet detection.
Results: For the control (no mask), 3.735 ± 0.543 μg of CPA was recovered from the aerated solution. Significantly
lower quantities were recovered from PCM (0.538 ± 0.098 μg) and PAM (0.236 ± 0.193 μg) (p < 0.001 and p < 0.001 vs
control, respectively). CPA quantities recovered from all of SAM samples were below the quantification limit. When a
piece of the SAM was immersed in the CPA solution, a marked decrease to less than 3.1 % of the initial CPA
concentration was observed.
Conclusion: The SAM exhibited good adsorption ability, and this characteristic may contribute to avoiding inhalation
exposure to vaporized CPA. These results suggest that wearing activated carbon masks may prevent anticancer drug
inhalation by healthcare workers.
Keywords: Activated carbon, Medical mask, Cyclophosphamide, Inhalation, Pleated-type, Stereoscopic-type,
Adsorption, Anticancer drug exposure
Background
Exposure of healthcare workers to anticancer drugs is a
serious concern, and may cause health hazards such as
carcinogenesis or genotoxicity. These concerns have
been supported by several studies, including our report
of anticancer drug pollution in a clinical setting, and re-
ports of human exposure to anticancer drugs detected in
the urine of healthcare workers [1–4]. Although
biological safety cabinets (BSCs) or closed system were
used in those cases, environmental pollution was still
observed. The main routes of occupational anticancer
drug exposure are inhalation, epicutaneous absorption,
and ingestion. Inhalation appears to be the main exposure
route [5].
Cyclophosphamide (CPA) is the most commonly
reported drug as an index of anticancer drug exposure.
This is because CPA vaporizes at room temperature
(≥23 °C), is carcinogenic and teratogenic, and is one of
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the most frequently prescribed drugs in cancer chemother-
apy [6]. Airborne CPA has been detected in anticancer drug
preparation environments [7, 8]. Vaporization can result
from CPA droplets scattering during preparation and from
spills, disposal of administration equipment, and handling
the patient’s excrement. Therefore, use of an N95 mask, or
other permeability-resistant mask, is strongly recommended
in Japanese guidelines when preparing anticancer drug injec-
tions (in particular when a BSC and closed system are not
used), cleaning preparation environments or spilled solu-
tions, and crushing or de-capsulating oral anticancer drugs
[9]. However, there has been no evaluation of the permeabil-
ity resistance of medical masks to vaporized anticancer
drugs such as CPA. Activated carbon adsorbs various che-
micals. We reported that a worksheet containing activated
carbon adsorbed anticancer drug droplets scattered during
preparation [10]. Therefore, the adsorption ability of the
mask containing activated carbon was expected to ad-
equately protect against the vaporized anticancer drug.
However, the ability of the activated carbon mask to prevent
the permeation of anticancer drugs is not evaluated using
similar means to that of a normal mask. This study investi-
gated the permeability of clinical-use masks to vaporized
CPA, and determined whether the inhibition of vaporized
CPA permeability was attributable to the mask’s adsorptive
ability. We also compared three types of masks with varying
properties with pleats type or stereoscopic type for a shape,
presence of the active carbon.
Methods
Materials
Pleated-type cotton masks (PCM) was used Disposable
surgical mask (No.433619) manufactured by Hasegawa
Menko Co., Ltd. (Nagoya, Japan). Pleated-type activated
carbon masks (PAM) was Hopes surgical mask (JM-28C)
manufactured by Japan Medical Products Co., Ltd.
(Asahikawa, Japan). Stereoscopic-type activated carbon
masks (SAM) was used Maskey MD manufactured by
Koken Co. Ltd. (Tokyo, Japan). The details of three kinds of
masks were indicated in Table 1. CPA was used Endoxan
infusion 500 mg manufactured by Shionogi & Co., Ltd.
(Osaka, Japan). As for the CPA determination by liquid
chromatography time-of-flight mass spectrometry (LC-
ITTOF-MS), liquid chromatography mass spectrometry
(LC/MS)-grade acetonitrile and distilled water (Wako Pure
Chemical Industries, Ltd., Osaka, Japan) were used. As for
the CPA determination by high-performance liquid chro-
matography (HPLC), HPLC-grade acetonitrile and distilled
water (Wako Pure Chemical Industries, Ltd., Osaka, Japan)
were used. Special grade ethanol (Wako Pure Chemical
Industries, Ltd., Osaka, Japan) was used.
Masks
Masks differed with respect to constituent materials (cot-
ton and activated carbon) and mask shape (stereoscopic
and pleated). These masks did not conform to the N95 or
DS2 criteria (≥95 % prevention performance of 0.1–0.3 μm
or 0.06–0.1 μm sodium chloride particle permeability).
However, these masks are used frequently in medical prac-
tice. Prevention of permeability by the PCM was ≥ 95 %, as
evaluated by particle filtration efficiency (PFE, mean particle
size 0.1 μm of latex) and bacterial filtration efficiency (BFE,
mean particle size 3.0 μm of bacteria), and that of
PAM was ≥ 95 %, when evaluated by BFE criteria. The
SAM could not be measured by either of these cri-
teria because this mask was designed to prevent the
Table 1 List of experimented mask
Mask type Pleated type cotton
mask (PCM)




Brand name, catalog number Disposable surgical mask
(No.433619)




Polypropylene and rayon non-woven
paper, fiberformed active carbon
Polyester and polyamide filter,
fiber-formed active carbon
(density of 200 g/m2)
Thickness 0.2 mm 1.0 mm 2.9 mm





for formaldehyde (0.5 ppm, 40 min)
and xylene (20 ppm, 43 min).
Manufacturer Hasegawa Menko Co.,
Ltd. Nagoya, Japan.
Japan Medical Products Co.,
Ltd. Asahikawa, Japan.
Koken Co. Ltd. Tokyo, Japan.
BFE Bacterial Filtration Efficiency (%), PFE Particle Filtration Efficiency (%)
Sato et al. Journal of Pharmaceutical Health Care and Sciences  (2016) 2:28 Page 2 of 7
inhalation of organic solvents. However, the material
(nonwoven paper) and structure of the SAM were similar
to those of the medical N95 mask. The SAM was used to
prevent inhalation of formaldehyde in hospital pathology
laboratories and in the handling of organic solvents.
Evaluation of CPA permeability of the mask
Figure 1 depicts a schematic illustration of the device
used for measuring CPA permeability. The vaporizing
method and CPA recovery have been described else-
where [11, 12]. CPA was used as the anticancer drug
and prepared to a solution of 2 mg/mL. The CPA
(4 mg/2 mL) was vaporized at 60 °C in a 1.1 L closed
chamber. The air containing the vaporized CPA was
passed through 100 cm2 of each mask using an air pump
(MP-Σ3; Shibata Science Co., Ltd., Saitama, Japan). The
flow rate was set to 1 L/min, which was the maximal
flow of the pump. The aeration and recovery time were
set for 1 h, when the quantity of CPA recovered reached
a maximum of 4 mg. The mask-passed air was aerated
in 10 mL of 50 % ethanol, and the CPA was collected for
quantity analysis. Ethanol was used as the recovery
medium because CPA readily dissolves in ethanol; how-
ever, the ethanol was diluted to 50 % to inhibit
vaporization of the ethanol by aeration. The CPA recov-
ery rate under these conditions was around 0.1 %.
Evaluation of CPA adsorptive ability of the mask
Figure 2 depicts a schematic illustration of CPA adsorptive
ability of the mask. To consider whether the prevention of
CPA permeability by each mask was attributable to the ad-
sorptive ability of the mask material, each mask piece
(5 cm2) was immersed in 10 mL of CPA solution and
shaken for 1 h at 20 °C before measuring the CPA concen-
tration. The CPA concentration setting established a con-
centration gradient (50–2,500 μg/mL) to observe an
adsorptive change from low to high concentrations more
than we used it for vaporization. After immersion of one
hour, CPA concentration of the solution was measured by
HPLC.
CPA measurement
To evaluate CPA permeability for each mask, we mea-
sured the quantity of CPA in the recovered solution by
LC-ITTOF-MS (Shimazu Co., Kyoto, Japan). For liquid
chromatography, 1 μL of the sample was injected into a
column (CAPCELL PAK ADME; 5 μm, 2.1 × 150 mm,
Shiseido, Tokyo, Japan) which was maintained at 40 °C
as a mobile phase at a flow rate of 0.2 mL/min with a
1:1 acetonitrile to water mixture. For mass spectrometry,
CPA was ionized by the electrospray ionization (ESI)
method, and fragments (m/z = 260.03) were detected in
the positive mode. The detection limit was 0.001 μg/mL.
Heater 
safety cabinet











Mask chamber ( 8.0cm)
Analysis sample
for LC-ITTOF-MS
Fig. 1 Schematic illustration of experimental equipment for the permeability of the mask for the vaporized CPA. Figure 1 indicated the schematic illustration
of experimental equipment for the permeability of the mask for the vaporized CPA. An aqueous solution of CPA (4 mg/2 mL) was vaporized in a chamber
(1.1 L) and maintained at 60 °C. The CPA including air passed through three types of masks (100 cm2) using an air pump at a flow rate of 1.0 L/min for
1 hour. The air which passed through these masks was recovered in 10 mL of 50 % ethanol solution, and assayed by liquid chromatography time-of-flight
mass spectrometry
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To evaluate the CPA-adsorptive ability of each mask,
CPA concentrations in the mask-immersed solutions were
determined using HPLC with ultraviolet detection
(Hitachi D-2000 Elite system; Hitachi High-Technologies
Co., Ltd., Tokyo, Japan) following a previous protocol [13].
Briefly, 20 μL of the sample were injected into a column
(LiChrosorb® RP-8; 5 μm, 2.1 × 150 mm, Merck KGaA,
Darmstadt, Germany) maintained at 40 °C as a mobile
phase at a flow rate of 1.0 mL/min with a 1:3 acetonitrile
to water mixture. CPA was measured by ultraviolet ab-
sorption at a wavelength of 195 nm. The detection limit
was 3 μg/mL.
Statistical analysis
Measurements were repeated four to five times in each
group; numerical values represent the mean ± standard
deviation. Differences between the groups were calcu-
lated by analysis of variance (ANOVA). If a significant
difference was detected, Tukey’s test for multiple com-
parisons was performed. Hazard ratios lower than 5 %
were considered statistically significant. The statistics
software used was Excel statistics 2012 (Social Survey
Research Information Co., Ltd., Tokyo, Japan).
Results
Evaluation of CPA permeability of the mask
Figure 3 represents the CPA permeability details for each
mask. The quantity of CPA recovered in the control
group (no mask) was 3.734 ± 0.543 μg. In contrast, use
of the mask significantly decreased the quantity of CPA
recovered (F3, 16 = 143.7, p < 0.001 by one-way ANOVA).
The CPA quantities recovered from the PCM and PAM
were significantly lower (0.538 ± 0.098 μg, p < 0.001, and
0.236 ± 0.193 μg, p < 0.001, respectively) than those re-
covered from the control. The quantity of CPA recov-
ered from the PAM was not significantly different from
that recovered from the PCM (p = 0.483). However, the
quantity of CPA recovered from the SAM was below the
quantitation limit. Among the five SAM measurements,
we failed to detect a peak in two of the measurements,
and the other three were below the quantitation limit.
Therefore, the quantity of CPA recovered from the SAM
was estimated at <0.006 μg.
Evaluation of CPA adsorptive ability of the mask
Figure 4 represents the CPA adsorptive ability of each
mask. The results of two-way ANOVA were as follows:
CPA concentration, F4, 60 = 11.1, p < 0.001; Mask, F3, 60 =
22,526.3, p < 0.001, and CPA concentration ×mask inter-
action, F12, 60 = 6.5, p < 0.001. CPA concentrations in the
PCM-immersed solutions were slightly lower than those
of the control. CPA concentrations in the PAM-immersed
Fig. 2 Schematic illustration of CPA adsorptive ability experiment. Figure 2 indicated a schematic illustration of CPA adsorptive ability of the mask.
Each mask piece (5 cm2) was immersed in various concentrations of CPA solutions (10 mL) and shaken for 1 h at 20 °C. After immersion of one hour,
CPA concentration of the solution was measured by HPLC
Fig. 3 Permeability of the masks for the vaporized CPA (n= 5). Fig. 3
indicated the permeability of the masks for the vaporized CPA. The
determination in each group was repeated four times. Each bar indicated
as mean± standard □;Control (no mask), ;PCM, ;PAM, ;SAM,
respectively. *** indicated a significant difference by Tukey test with less
than 0.1 % of hazard ratio as compared with Control. SAM indicated
below the limit of quantification
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solutions were significantly lower than those of the
control and PCM. However, the decrease was minimal,
with 87.2–93.8 % of the initial concentrations remaining.
In contrast, CPA concentrations were markedly lower in
the SAM-immersed solutions, and lower than the limit of
detection at 50–1,000 μg/mL of the initial concentrations.
Although CPA was detected at 2500 μg/mL, a significant
decrease was found, with only 3.1 % of the initial concen-
tration remaining.
Discussion
In the previous studies, environmental pollution and
human exposure were reported even when a BSCs was
used [13]. A pollution survey undertaken in our hospital
found environmental pollution of fluorouracil (5-FU)
and CPA outside the BSC even though a closed system
was used for preparing and handling CPA [1]. For this
reason, it was thought that an air barrier might fail upon
movement of arms of persons in and out of the cabinet
during preparation from Class IIb BSC. It was also
thought that anticancer drugs scattered at a preparation
would adhere to the infusion surface, and flow out of
the BSCs with the infusion bag or bottle [14]. Drugs
leaking out of the BSCs would cause human exposure
through adhesion to skin or inhalation of the vaporized
form. Therefore, wearing a mask is essential.
The particle diameter and physicochemical properties
(mist form or molecular form) of the vaporized CPA in
this study were unclear. However, a difference in the
quantity of recovered CPA was observed when vaporized
CPA was filtered through three mask types. The PCM
had a ≥ 95 % prevention of permeability, as evaluated by
PFE (mean particle size 0.1 μm of latex). The findings
implied that the masks trapped most of the CPA, includ-
ing particles with a ≥ 0.1 μm diameter. The quantity of
CPA that permeated the mask decreased by 85.6 % com-
pared with the amount detected under conditions with-
out the mask, even with the PCM. Therefore, wearing
the mask might be effective, to some extent, in reducing
the inhalation of the anticancer drug droplets. However,
some of the CPA filtered through the mask and was re-
covered in this study. The diameter of the vaporized
CPA, in either molecular or particle form, may have
been smaller than the captured range of the mask. This
suggests that inhalation of vaporized CPA cannot be pre-
vented completely with a normal surgical mask. A simi-
lar phenomenon was reported in a study evaluating the
reactive oxygen species (ROS) permeability of various
masks. Removal efficiencies of particle-form ROS were
83.5–94.1 %, but those of gaseous ROS were only 1.3–
21.1 % [15]. The quantity of CPA recovered from the
SAM implied very low permeability to CPA (no peak
detection in two of five samples, and below the quantita-
tion limit in the other three). This good performance of
the SAM may have resulted from trapping of gaseous
CPA, as well as particle-form CPA, by the activated
carbon. To assess this possibility, we immersed mask
pieces in aqueous CPA solutions and examined the
change in CPA concentration. The masks containing
activated carbon (PAM and SAM) decreased CPA concen-
trations in the solution to a greater extent than PCM,
which did not contain activated carbon. These differences
appear to be attributable to the activated carbon. In par-
ticular, SAM showed stronger CPA adsorption than PAM.
This difference is thought to contribute to the anti-
permeability property against vaporized CPA. The density
Fig. 4 Absorptive ability of the mask immersed in the CPA solution (n = 4). Fig. 4 indicated the absorptive ability of the mask immersed in the
CPA solution. The determination in each group was repeated five times. Each bar indicated as mean ± standard deviation with □;Control (no
mask), ;PCM, ;PAM, ;SAM, respectively. *, **, and *** indicated significant differences by Tukey test with less than 5 %, 1 %, and 0.1 % of
hazard ratio as compared with Control, respectively. †† and ††† indicated a significant difference by Tukey test with less than 0.1 % and 1 % of
hazard ratio as compared with PCM. ‡‡‡ indicated a significant difference by Tukey test with less than 0.1 % of hazard ratio as compared with
PAM. 50–1000 μg/mL in the SAM indicated below the limit of quantification
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of activated carbon in SAM was high (200 g/m2). Al-
though the density of activated carbon in PAM was not
specified by the manufacturer, the thickness of the acti-
vated carbon was smaller macroscopically than that of the
carbon in SAM. Anticancer drugs have been detected in
masks used by healthcare workers engaged in preparing
the drugs [3, 4]. Therefore, the drug adsorptive ability of
the activated carbon mask would seem to be a beneficial
factor in preventing anticancer drug exposure in health-
care workers.
This study had some limitations. The use of a mask
with N95 standard or superior performance is recom-
mended in Japanese guidelines [9]. However, the three
mask types used in this study were not examined with
regard to the N95 criteria. Generally, the filtration effi-
ciency of pleats-type surgical masks, for particles with
>0.1 μm diameter, is approximately 20–30 % lower than
that of the N95 mask [16]. Furthermore, a leak may re-
sult from a gap between the face and the mask, depend-
ing on mask design and appropriate use by the
healthcare worker, subsequently affecting filtration
efficiency. If the mask does not fit well, its filtration effi-
ciency is decreased as air bypasses the filter. Rengasamy
et al. reported that leaks were greater in pleats-type
masks than in stereoscopic-type masks [17]. However, in
this study condition, the mask which cut to 100 cm2 was
pinched with two funnels, and was ventilated as a flat
shape. Therefore, it was thought that the difference of
the mask shape was not reflected in this results. The ef-
fectiveness of preventing anticancer drug inhalation for
the clinical application might be lower than this study
results. In addition, our study has limitations concerning
experimental conditions. The prevention of drug perme-
ability by the mask might be due to the low recovery
rate of 50 % ethanol. Although a considerable amount of
CPA may penetrate the mask, the ability of the mask to
prevent drug permeation might have been overestimated
as by low CPA recovery rate. It is uncertain whether the
medical practice environment in which anticancer drugs
are prepared and administered was correctly replicated
in this study. The respiration rate of a human at rest is
8–11 L/min (https://unit.aist.go.jp/riss/crm/exposurefac-
tors/documents/factor/body/breathing_rate.pdf. go.jp
/riss/crm/exposurefactors/); the air flow in our study
was carried out at one-tenth of that rate. When the air-
flow is faster, the adsorption of gaseous CPA might de-
crease because the drug’s contact time with activated
carbon is shorter. Moreover, permeability was only eval-
uated for 1 h. This may be considered short compared
to mask exchange cycles in clinical settings. With pro-
longed use, CPA may filter through the mask. We se-
lected CPA because it is easy to volatilize and is a strong
anticancer drug. The ability of anticancer drugs such as
ifosfamide and CPA to vaporize and pollute clinical
settings has been known [11, 18]. In addition, 5-FU and
methotrexate have been detected in hospital air samples
[18]. Future studies should investigate permeability of
the mask for drugs other than CPA as well.
The CPA occupational exposure limit has been
estimated at 0.1 μg/m3/day [19]. A healthcare worker is
estimated to inhale approximately 3840–5280 L of air over
the course of 8 h. Though the bioavailability of inhaled
CPA is unknown, the CPA concentrations permitted in
healthcare workers with normal body surface (1.73 m2 are
estimated at 0.03–0.05 ng/L. CPA pollution in studies of
hospital air samples were reported as <0.04–10.1 ng/L [7]
and 0.24 ng/L [8]. Inhalation without a mask in a clinical
polluted environment might to exceed daily CPA exposure
limits. SAM decreased the CPA permeation quantity by
>99.8 % compared with that under conditions without the
mask. When SAM is used in a medical environment simi-
lar to what may occur during inhalational CPA exposure,
the inhaled CPA may be expected to less than the daily ex-
posure tolerance limit. Therefore, the use of activated car-
bon masks may be a better choice than the use of other
types of masks.
This study was the first to report the examination of
the permeability of medical masks to aerosolized anti-
cancer drugs. Furthermore, the performance differences
between masks containing activated carbon and normal
masks were examined. The mask containing a particular
kind of activated carbon (SAM) showed good prevention
of permeability. The ability of the activated carbon to
adsorb the anticancer drug was suggested as an under-
lying mechanism of its effectiveness. In future studies,
we expect the development of the N95 criteria for med-
ical masks containing activated carbon. It may be neces-
sary to evaluate performance of activated carbon mask
with N95 criteria by monitoring urinary levels of anti-
cancer drugs or their metabolites in healthcare workers.
Conclusion
The use of activated carbon masks to healthcare workers
might prevent anticancer drug inhalation.
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